Fresenius SE & Co. KGaA · XETR:FRE
Fresenius SE & Co. KGaA — Non-Deal Roadshow (March 2019)
67 slides from Fresenius SE & Co. KGaA's roadshow presentation, Mar 28, 2019
Slide 1: Roadshow Hong Kong
Roadshow Hong Kong Hong Kong, 28 March 2019 Frankfurt stock exchange: FRE │ US ADR program: FSNUY │ www.fresenius.com/investors
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive
Slide 3: A Global Leader In HealthCare Products And Services
A Global Leader In HealthCare Products And Services ~€33.5 bn in Sales Global presence in (as of Dec. 31, 2018) 100+ countries Total Shareholder Return: 10-year CAGR: ~15% Strong portfolio 275,000+ employees of products (30% of sales) worldwide and services (70% of sales) (as of December 31, 2018) R
Slide 4: Strong and Balanced Health Care Portfolio
Strong and Balanced Health Care Portfolio Ownership: ~31% Ownership: 100% Ownership: 100% Ownership: 77% Dialysis Products Hospital Supplies Hospital Operation Projects and Services for Health Care Services Hospitals • Dialysis services • IV drugs • Acute care • Post-acute care • Hemodialysis produc
Slide 5: Total Shareholder Return – CAGR, Rounded
Total Shareholder Return – CAGR, Rounded 10 years 15 years 20 years 15% 14% 13% 12% 10% 9% 8% 8% 7% 6% 6% 4% DAX S&P 500 Fresenius MSCI World Fresenius DAX S&P 500 Fresenius MSCI World Fresenius DAX S&P 500 MSCI World Fresenius Fresenius Health Care Health Care Health Care Source: Bloomberg; dividen
Slide 6: Fresenius Medical Care: Global Dialysis Market Leader
Fresenius Medical Care: Global Dialysis Market Leader • The world’s leading provider of dialysis products Market Dynamics and services treating more than 330,000 patients1 in ~3,900 clinics1 Global Dialysis Market 2018: • Provide highest standard of product quality and • ~€71 bn • ~6% patient growth
Slide 7: Fresenius Kabi: A Leading Global Hospital Supplier
Fresenius Kabi: A Leading Global Hospital Supplier • Comprehensive product portfolio for critically and Market Dynamics chronically ill patients • Strong Emerging Markets presence Global Addressable Market 2018: • Leading market positions in four product • ~€81 bn segments Growth Drivers: • Patent e
Slide 8: Fresenius Helios: Europe's Largest Private Hospital Operator Helios Germany
Fresenius Helios: Europe’s Largest Private Hospital Operator Helios Germany • ~5%1 share in German acute care hospital Market Dynamics market • Organic growth based on growing number of German Acute Care Hospital Market: admissions and reimbursement rate increases • ~€102 bn2 • Ranks as quality lead
Slide 9: Fresenius Helios: Europe's Largest Private Hospital Operator Helios Spain
Fresenius Helios: Europe’s Largest Private Hospital Operator Helios Spain • ~€3.0 bn sales in 2018 Market Dynamics • ~12%1 share in Spanish private hospital market Spanish Private Hospital Market: • Market leader in size and quality with excellent • ~€14 bn2 growth prospects Growth Drivers: • Broad
Slide 10: Fresenius Vamed: Leading Global Hospital Projects and Services Specialist
Fresenius Vamed: Leading Global Hospital Projects and Services Specialist • Manages hospital construction/expansion Market Dynamics projects and provides services for health care facilities worldwide Growth Drivers: • Offers project development, planning, turnkey • Emerging Market demand for buildin
Slide 11: Fresenius Group
Fresenius Group ● Delivered on FY/18 Group targets ● 26th consecutive dividend increase proposed ● Significant investments into medium-term growth in FY/18 and FY/19 ● Fresenius Kabi expected to show continued growth in FY/19 ● Helios Germany impacted by regulatory changes and initiatives to secure
Slide 12: Fresenius Kabi: Significant investments
Fresenius Kabi: Significant investments IV Generics • ~US$350 million investment in Melrose Park, USA Installation of state-of-the-art sterile pharmaceutical production, packaging technologies and related laboratories • ~ US$120 million investment in Grand Island, USA, New production lines and o
Slide 13: Fresenius Kabi: US Generic IV Drug Market in FY/19
Fresenius Kabi: US Generic IV Drug Market in FY/19 2019 pricing environment expected to be Excellent competitive position - strong in line with recent years customer relationships and pipeline • Key molecules to see more competition, • FDA accelerated approvals of generics – however broadly unchange
Slide 14: Helios Germany: Improved visibility
Helios Germany: Improved visibility Active management of regulatory New business models challenges by adjusting structures • Develop internationally scalable business models • Clustering (to fulfill minimum number of • New business areas for Germany (e.g. video indications) consulting, occupational
Slide 15: Helios Spain: Continued dynamic growth
Helios Spain: Continued dynamic growth Growth projects Innovative projects • Acquisition Clínica Medellin, Colombia • Proton Therapy Center Closing expected in Q1/19 First proton therapy center in Spain with a total investment of €40 million ~€50 million investment Construction project is on
Slide 16: Fresenius Group: Portfolio alignment and cost savings
Fresenius Group: Portfolio alignment and cost savings to improve profitability and fuel growth trajectory • Reshaping German hospital • Cost optimization network to lead regulatory program on top of changes GEP II initiated • Focus on process optimization • Strategic review of and improved patient s
Slide 17: Fresenius Group: Capital deployment
Fresenius Group: Capital deployment centers on sustainable long-term value creation Re- Fuel organic growth with low-risk high- investments in return investments own business Short-term focus on small bolt-on Strategic acquisitions; long-term rigorous pursuit of acquisitions inorganic growth traject
Slide 18: Fresenius Group: Healthy Growth Targets 2020 - 2023
Fresenius Group: Healthy Growth Targets 2020 - 2023 Growing Markets with High Marketing of existing Attractive markets Entry Barriers value chain Strengthening and Attractive Product Pipeline Market consolidation extension of value chain Entry into attractive Development of post- Synergies biosimila
Slide 19: Financial Review FY/18
Financial Review FY/18 Roadshow Hong Kong, 28 March 2019 © Fresenius SE & Co. KGaA Investor Relations 19
Slide 20: Fresenius Group: Q4/18 & FY/18 Profit and Loss Statement
Fresenius Group: Q4/18 & FY/18 Profit and Loss Statement €m Q4/18 Δ YoY cc FY/18 Δ YoY cc Sales 8,835 7%1 33,530 6%1 EBIT 1,250 0% 4,561 -1%/1%2 EBIT (excl. biosimilars) 1,303 0% 4,727 1%/3%2 Net interest -129 12% -570 7% Income taxes -253 17% -880 21% Net income 504 5% 1,871 7% Net income (excl. bi
Slide 21: Fresenius Group: Q4/18 Business Segment Growth
Fresenius Group: Q4/18 Business Segment Growth Organic sales growth EBIT growth (cc) +6% 12%2 +7% 6%/8%3 +4% -2%/2%4 +20% 39%/11%4 +6%1 0%2/0%2,3 1 Growth rates adjusted for IFRS 15 adoption and divestitures of Care Coordination activities 2 EBIT reported 3 Excl. biosimilars 4 Adjusted for transfer
Slide 22: Fresenius Kabi: Organic Sales Growth by Regions
Fresenius Kabi: Organic Sales Growth by Regions Δ YoY Δ YoY €m Q4/18 organic FY/18 organic North America 599 5% 2,359 8% Europe 590 3% 2,248 3% Asia-Pacific/Latin 498 15% 1,937 12% America/Africa Asia-Pacific 336 13% 1,300 12% Latin America/Africa 162 18% 637 13% Total sales 1,687 7% 6,544 7% Roadsh
Slide 23: Fresenius Kabi: Q4 & FY/18 EBIT Growth
Fresenius Kabi: Q4 & FY/18 EBIT Growth €m Q4/18 Δ YoY cc FY/18 Δ YoY cc North America 216 9% 894 10% Margin 36.1% 110 bps 37.9% 70 bps Europe 97 -9% 355 3% Margin 16.4% -210 bps 15.8% -10 bps Asia-Pacific/Latin America/Africa 116 22% 398 14% Margin 23.3% 140 bps 20.5% 40 bps Corporate and Corporate
Slide 24: Fresenius Kabi: Expected Organic Sales Growth 2019
Fresenius Kabi: Expected Organic Sales Growth 2019 North America Low to mid-single-digit growth • Growth in 2019 mainly driven by new drug launches and further ramp-up of pre-filled syringe business • More competition for key molecules; broadly unchanged pricing environment in base business • Contin
Slide 25: Fresenius Kabi: Expected Organic Sales Growth 2019
Fresenius Kabi: Expected Organic Sales Growth 2019 Emerging Markets Likely double-digit growth China: • Attractive growth prospects • Growth particularly driven by Clinical Nutrition and IV drugs Asia-Pacific ex China: • Very positive sentiment Latin America/Africa: • Strong growth momentum expected
Slide 26: Fresenius Helios
Fresenius Helios Helios Germany Helios Spain • Organic sales growth of 3% in Q4/18 – • Strong sales growth of 8% in Q4/18 DRG price increases and better results from • Additional month of consolidation the negotiations with our payors offset contributed significantly to 17% sales decline in admissio
Slide 27: Fresenius Helios: Q4 & FY/18 Key Financials
Fresenius Helios: Q4 & FY/18 Key Financials €m Q4/18 Δ YoY FY/18 Δ YoY Total sales 2,231 -1%/4%2 8,993 4%/6%2 Thereof Helios Germany 1,439 -5%/3%2 5,970 -2%/2%2 Thereof Helios Spain1 792 8% 3,023 17% Total EBIT 277 -2%/2%2 1,052 0%/3%2 Margin 12.4% -20 bps 11.7% -40 bps Thereof Helios Germany 137 -2
Slide 28: Fresenius Vamed
Fresenius Vamed • Both business segments contributed to the €m Q4/18 Δ YoY FY/18 Δ YoY excellent organic sales growth of 16% in Total sales 697 45% 1,688 37% FY/18 22%1 19%1 • Sales share of more stable and high Thereof margin service business clearly outstrips organic sales 20% 16% project business
Slide 29: Fresenius Group: Cash Flow
Fresenius Group: Cash Flow Operating CF Capex (net) Free Cash Flow1 €m Q4/18 LTM Margin Q4/18 LTM Margin Q4/18 LTM Margin 220 15.9% -201 -8.5% 19 7.4% 167 6.2% -176 -4.9% -9 1.3%2 108 6.3% -15 -1.7% 93 4.6% Corporate/Other 0 n.a. -28 n.a. -28 n.a. Excl. FMC 495 10.4%3 -420 -6.3% 75 4.1%3 Q4/18 1,193
Slide 30: Fresenius Group: 2019 Financial Outlook by Business Segment
Fresenius Group: 2019 Financial Outlook by Business Segment €m (except otherwise stated) FY/18 Base FY/19e1 Sales growth (org) 6,544 3% - 6% EBIT growth (cc) 1,1392 3% - 6% Sales growth (org) 8,993 2% - 5% EBIT growth 1,052 -5% to -2% Sales growth (org) 1,688 ~10% EBIT growth 110 15% - 20% 1 Excludi
Slide 31: Fresenius Group: 2019 Financial Guidance
Fresenius Group: 2019 Financial Guidance €m (except otherwise stated) FY/18 Base1 FY/192 Sales growth (cc) 33,009 3% - 6% Net income3 growth (cc) 1,872 ~0% 1 Before special items and after adjustments 2 Excluding transaction-related expenses, expenses associated with the cost optimization program at
Slide 32: Fresenius Group: Healthy Growth Targets 2020 – 2023 (CAGRs)
Fresenius Group: Healthy Growth Targets 2020 – 2023 (CAGRs) Organic sales growth 4 – 7% (plus ~1% small to mid- size acquisitions) Organic net income1 growth 5 – 9% (plus ~1% small to mid- size acquisitions) 1 Net income attributable to shareholders of Fresenius SE & Co. KGaA Before special items Ro
Slide 33: Attachments
Attachments Roadshow Hong Kong, 28 March 2019 © Fresenius SE & Co. KGaA Investor Relations 33
Slide 34: FY/18 base for Fresenius Group Guidance FY/19
FY/18 base for Fresenius Group Guidance FY/19 €m Sales reported 33,530 Divestitures of Care Coordination activities at FMC (H1/18) -521 Sales basis for growth rates 33,009 Net Income reported 2,027 Transaction Costs, Akorn, Biosimilars 25 Bridge Financing Costs Akorn 12 Revaluations of Biosimilars c
Slide 35: FY/18 base for Fresenius Medical Care Outlook FY/19
FY/18 base for Fresenius Medical Care Outlook FY/19 €m Sales reported 16,547 Divestitures of Care Coordination activities at FMC (H1/18) -521 Sales basis for growth rates 16,026 Net Income reported 1,982 Impact of FCPA related charge 28 Gain related to divestitures of Care Coordination activities -6
Slide 36: FY/18 base for Fresenius Kabi Outlook FY/19
FY/18 base for Fresenius Kabi Outlook FY/19 €m Sales basis for growth rates 6,544 Transaction Costs Akorn, Biosimilars 34 Revaluations of Biosimilars contingent liabililties 7 EBIT (before special items = base for Kabi guidance) 1,139 The special items are reported in the Group Corporate/Other segme
Slide 37: IFRS 16: Profit and Loss - Implications
IFRS 16: Profit and Loss - Implications €m Expected IFRS 16 effect on 2019 Sales - ~€0.1 bn (discontinuation of sale-leaseback transactions at FMC NA) EBITDA + ~€1.0 bn (fewer rent expenses) Depreciation and amortization - ~€0.9 bn (additional depreciation) EBIT + ~€0.1 bn Interest - ~€0.2 bn (addit
Slide 38: IFRS 16: Balance Sheet
IFRS 16: Balance Sheet €m Expected IFRS 16 effect on 2019 Right-of-use-asset ~€5.2 bn Lease liability ~€5.5 bn Equity ~-€0.3 bn Leverage + ~30-40 bps Leases have to be recognized as a right-of-use-asset and corresponding liability Roadshow Hong Kong, 28 March 2019 © Fresenius SE & Co. KGaA Investor
Slide 39: 26th Consecutive Dividend Increase
Fresenius Group: 26th Consecutive Dividend Increase CAGR +16% 0.75 0.801 0.62 0.55 0.32 0.37 0.42 0.44 € 0.29 0.23 0.25 0.22 0.19 0.16 0.02 '93 '05 '06 '07 '08 '09 '10 '11 '12 '13 '14 '15 '16 '17 '18 Dividend growth aligned to EPS growth Pay-out ratio: 24% 1 Proposal Roadshow Hong Kong, 28 March 201
Slide 40: Fresenius Group: Profit and Loss Statement
Fresenius Group: Profit and Loss Statement Growth Q4 YoY Growth FY YoY actual constant actual constant €m Q4/2018 rates rates FY/2018 rates rates Sales 8,835 7%1 7%1 33,530 2%1 6%1 EBIT 1,250 0% 0% 4,561 -4% -1% Net interest -129 12% 12% -570 10% 7% Income taxes -253 18% 17% -880 23% 21% Net income2
Slide 41: Fresenius Group: Calculation of Noncontrolling Interest
Fresenius Group: Calculation of Noncontrolling Interest €m FY/18 FY/17 Earnings before tax and noncontrolling interest 3,991 4,178 Taxes -880 -1,168 Noncontrolling interest, thereof -1,240 -1,194 Fresenius Medical Care net income not attributable to -925 -864 Fresenius (FY/18: ~69%) Noncontrolling i
Slide 42: Fresenius Group: Cash Flow
Fresenius Group: Cash Flow €m Q4/18 LTM Margin Δ YoY Operating Cash Flow 1,193 11.2% 7% Capex (net) -721 -6.2% -22% Free Cash Flow 472 5.0% -10% (before acquisitions and dividends) Acquisitions (net) -198 Dividends -72 Free Cash Flow 202 4.1% -70% (after acquisitions and dividends) Roadshow Hong Kon
Slide 43: Fresenius Group: FY/18 & LTM Cash Flow
Fresenius Group: FY/18 & LTM Cash Flow Operating CF Capex (net) Free Cash Flow1 €m FY/2018 LTM Margin FY/2018 LTM Margin FY/2018 LTM Margin 1,040 15.9% -553 -8.5% 487 7.4% 554 6.2% -434 -4.9% 120 1.3%3 106 6.3% -29 -1.7% 77 4.6% Corporate/Other -20 n.a. -58 n.a. -78 n.a. Excl. FMC 1,680 10.4%2 -1,07
Slide 44: Group: Leverage Ratio
Fresenius Group: Leverage Ratio 4,00 4.0 Net Debt/EBITDA target 2019 Broadly on the level2 of year-end 2018 3.5 3,50 3.22 3.02 3.02 3 2.98 2.96 3 3 3,00 3.0 2.91 3.00 2.97 2.98 2.84 2.80 2.75 2.71 2.67 2.65 2,50 2.5 2.59 2.55 2.53 2.33 2,00 2009 2010 2011 2012 2013 1 2014 2015 2016 Q1 Q2 Q3 Q4 Q1 Q2
Slide 45: Fresenius Group Consistent Cash Generation
Fresenius Group Consistent Cash Generation CFFO margin FCF margin (before acquisitions & dividends) % % 14 10 13 12.6 12.2 7.4 7.6 12.0 12.0 8 11.4 11.6 6.7 6.7 6.6 12 11.2 6.3 6.2 11.0 5.6 11 6 5.2 5.0 10.9 10 10.3 4 8.7 2.7 9 8 2 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2008 2009 201
Slide 46: Fresenius Group: Solid Balance Sheet Structure
Fresenius Group: Solid Balance Sheet Structure Assets Equity + Liabilities Equity + Minority 41% 44% interest Non-current assets 74% 76% 36% 33% Debt Receivables 11% 12% 23% 23% Other 15% Other 12% Dec 31, 17 Dec 31, 18 Dec 31, 17 Dec 31, 18 B/S total (€m) 53,133 56,703 53,133 56,703 Roadshow Hong K
Slide 47: Group: Well Balanced Financing Mix and Maturity Profile
Fresenius Group: Well Balanced Financing Mix and Maturity Profile Financing mix Maturity profile1,2 €m Other Debt 4.000 Bonds 47% 6% Commercial Paper 3.000 10% Equity neutral Total debt 2.000 convertible bond €18,984 m 7% Schuldschein loans 1.000 9% 0 Syndicated credit facilities 21% Fresenius Medic
Slide 48: Fresenius Kabi: Organic Sales Growth by Product Segment
Fresenius Kabi: Organic Sales Growth by Product Segment Δ YoY Δ YoY €m Q4/18 organic FY/18 organic IV Drugs 710 5% 2,735 5% Infusion Therapy 226 1% 929 7% Clinical Nutrition 458 15% 1,796 13% Medical Devices/ 293 5% 1,084 4% Transfusion Technology Total sales 1,687 7% 6,544 7% Roadshow Hong Kong, 28
Slide 49: Fresenius Kabi: Profit and Loss Statement
Fresenius Kabi: Profit and Loss Statement €m FY/18 FY/17 Sales 6,544 6,358 EBITDA 1,434 1,483 margin % 21.9 23.3 EBIT 1,139 1,177 margin % 17.4 18.5 Net interest -108 -119 EBT and noncontrolling interest 1,031 1,058 Income taxes -246 -317 Tax rate % 23.9 30.0 Noncontrolling interest -43 -39 Net inco
Slide 50: Fresenius Kabi: Cash Flow Statement
Fresenius Kabi: Cash Flow Statement €m FY/18 FY/17 Net income 756 739 (incl. noncontrolling interest) Depreciation / amortization 295 306 Change in working capital -11 -35 Cash flow from operations 1,040 1,010 Margin % 15.9 15.9 CAPEX, net -553 -420 Free Cash flow 487 590 (before acquisitions and di
Slide 51: Fresenius Kabi: Balance Sheet
Fresenius Kabi: Balance Sheet €m FY/18 FY/17 Accounts receivable 883 841 Inventories 1,521 1,361 Fixed assets 8,593 8,092 Other assets 1,641 1,498 Total assets 12,638 11,792 Debt 3,867 4,806 Other liabilities 3,279 2,997 Equity (incl. noncontrolling interest) 5,492 3,989 Total liabilities and shareh
Slide 52: Fresenius Helios: Key Measures
Fresenius Helios: Key Measures FY/18 FY/17 Δ No. of hospitals Germany 86 111 -23% - Acute care hospitals 83 88 -6% No. of hospitals Spain 47 45 4% (Hospitals) No. of beds Germany 29,329 34,610 -15% - Acute care hospitals 28,802 29,438 -2% No. of beds Spain 7,019 6,652 6% (Hospitals) Admissions Germa
Slide 53: Fresenius Helios: Profit & Loss Statement
Fresenius Helios: Profit & Loss Statement €m FY/18 FY/17 Sales 8,993 8,668 EBITDA 1,429 1,426 Margin % 15.9 16.5 Depreciation / amortization -377 -374 EBIT 1,052 1,052 Margin % 11.7 12.1 Net interest -167 -155 EBT 885 897 and noncontrolling interest Income taxes -189 -164 Tax rate % 21.4 18.3 Noncon
Slide 54: Fresenius Helios: Cash Flow
Fresenius Helios: Cash Flow €m FY/18 FY/17 Net income 696 733 (incl. noncontrolling interest) Depreciation / amortization 377 374 Change in working capital -519 -374 Cash flow from operations 554 733 Margin % 6.2 8.5 CAPEX, net -434 -411 Cash flow 120 322 before acquisitions and dividends Acquisitio
Slide 55: Fresenius Helios: Balance Sheet
Fresenius Helios: Balance Sheet €m FY/18 FY/17 Accounts receivable 2,110 1,840 Property, plant and equipment (net) 3,922 4,113 Goodwill 7,857 7,902 Other assets 2,615 2,728 Total assets 16,504 16,583 Debt 6,219 6,665 Other liabilities 2,526 2,529 Equity 7,759 7,389 (incl. noncontrolling interest) To
Slide 56: Fresenius Vamed: Profit & Loss Statement
Fresenius Vamed: Profit & Loss Statement €m FY/18 FY/17 Sales 1,688 1,228 EBITDA 133 87 Margin % 7.9 7.1 EBIT 110 76 Margin % 6.5 6.2 Net interest -9 -2 EBT and noncontrolling interest 101 74 Income taxes -28 -23 Tax rate % 27.3 31.1 Noncontrolling interest -1 -1 Net income1 72 50 ROE (before taxes)
Slide 57: Fresenius Vamed: Cash Flow
Fresenius Vamed: Cash Flow €m FY/18 FY/17 Net income (incl. noncontrolling interest) 73 51 Depreciation / amortization 23 11 Change in working capital 10 -20 Cash flow from operations 106 42 Margin % 6.3 3.4 CAPEX, net -29 -7 Free Cash flow (before acquisitions and 77 35 dividends) Margin % 4.6 2.9
Slide 58: Fresenius Vamed: Balance Sheet
Fresenius Vamed: Balance Sheet €m FY/18 FY/17 Accounts receivable 392 238 Property, plant and equipment 411 80 Intangible assets 308 127 Other assets 1,049 837 Total assets 2,160 1,282 Debt 535 245 Other liabilities 959 648 Equity (incl. noncontrolling interest) 666 389 Total liabilities and shareho
Slide 59: Fresenius Group: Reconciliation
Fresenius Group: Reconciliation growth rate €m FY/18 FY/17 growth rate (cc) Sales reported 33,530 33,886 -1% 2% Adjustments from IFRS 15 - -486 Divestitures of Care Coordination activities (H2/2017) at - -559 Fresenius Medical Care (FMC) Sales basis for growth rates 33,530 32,841 2% 6% EBIT reported
Slide 60: Fresenius Group: Reconciliation
Fresenius Group: Reconciliation growth rate €m FY/18 FY/17 growth rate (cc) Income taxes reported (after special items) -950 -889 -7% -11% Transaction Costs Akorn, biosimilars -10 -9 Bridge Financing Costs Akorn -5 -4 Revaluations of biosimilars contingent liabilities -2 - Impact of FCPA related cha
Slide 61: Fresenius Group: Reconciliation
Fresenius Group: Reconciliation growth rate €m FY/18 FY/17 growth rate (cc) Net income reported (after special items) 2,027 1,814 12% 15% Transaction Costs Akorn, biosimilars 25 32 Bridge Financing Costs Akorn 12 11 Revaluations of biosimilars contingent liabilities 5 - Impact of FCPA related charge
Slide 62: Fresenius Medical Care: Reconciliation
Fresenius Medical Care: Reconciliation growth rate €m FY/18 FY/17 growth rate (cc) Sales reported 16,547 17,784 -7% -2% Effect from IFRS 15 implementation - -486 Divestitures of Care Coordination activities (H2/2017) - -559 Revenue on a comparable basis 16,547 16,739 -1% 4% VA Agreement1 - -94 Sales
Slide 63: Fresenius Medical Care: Reconciliation to Fresenius Group
Fresenius Medical Care: Reconciliation to Fresenius Group growth rate €m FY/18 FY/17 growth rate (cc) EBIT reported (after special items) 3,038 2,362 29% 33% Gain related to divestitures of Care Coordination activities -809 - Impact of FCPA1 related charge 77 200 EBIT (before special items) 2,306 2,
Slide 64: Fresenius Kabi: Reconciliation
Fresenius Kabi: Reconciliation growth rate €m FY/18 FY/17 growth rate (cc) Sales reported 6,544 6,358 3% 7% Transaction Costs Akorn, biosimilars 34 41 Revaluations of biosimilars contingent liabilities 7 - EBIT (before special items) 1,139 1,177 -3% 2% Expenditure for further development of biosimil
Slide 65: Fresenius Helios: Reconciliation
Fresenius Helios: Reconciliation growth rate €m FY/18 FY/17 growth rate (cc) Sales reported 8,993 8,668 4% - German post-acute care business transferred from 230 - - Fresenius Helios to Fresenius Vamed Sales adjusted 9,223 8,668 6% - EBIT reported 1,052 1,052 0% - German post-acute care business tra
Slide 66: Fresenius Vamed: Reconciliation
Fresenius Vamed: Reconciliation growth rate €m FY/18 FY/17 growth rate (cc) Sales reported 1,688 1,228 37% - German post-acute care business transferred from -230 - - Fresenius Helios to Fresenius Vamed Sales adjusted 1,458 1,228 19% - EBIT reported 110 76 45% - German post-acute care business trans
Slide 67: Financial Calendar / Contact
Financial Calendar / Contact Financial Calendar 02 May 2019 Results Q1/19 17 May 2019 Annual General Meeting 30 July 2019 Results Q2/19 29 October 2019 Results Q3/19 Please note that these dates could be subject to change. Contact Investor Relations Fresenius SE & Co. KGaA phone: +49 6172 608-2485 e
Fresenius SE & Co. KGaA — Non-Deal Roadshow (March 2019) on 6ix